JP2024540044A5 - - Google Patents
Info
- Publication number
- JP2024540044A5 JP2024540044A5 JP2024525160A JP2024525160A JP2024540044A5 JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5 JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- cycle
- mosnetuzumab
- day
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025155232A JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/057439 WO2023075798A1 (en) | 2021-10-29 | 2021-10-29 | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155232A Division JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540044A JP2024540044A (ja) | 2024-10-31 |
| JP2024540044A5 true JP2024540044A5 (cg-RX-API-DMAC7.html) | 2025-05-20 |
| JP7846761B2 JP7846761B2 (ja) | 2026-04-15 |
Family
ID=86158448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525160A Active JP7846761B2 (ja) | 2021-10-29 | 2021-10-29 | モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 |
| JP2025155232A Pending JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155232A Pending JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性/難治性濾胞性リンパ腫の処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JP7846761B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240093915A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021471006A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236111A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005105A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20241211A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023075798A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006456A1 (en) * | 2024-06-25 | 2026-01-02 | Genentech, Inc. | Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide |
| TW202615094A (zh) * | 2024-08-28 | 2026-04-16 | 美商建南德克公司 | 使用莫蘇妥珠單抗與帕羅托珠單抗維多汀組合之皮下給藥治療癌症之方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021022815A2 (pt) | 2019-05-14 | 2021-12-28 | Genentech Inc | Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina |
-
2021
- 2021-10-29 AU AU2021471006A patent/AU2021471006A1/en active Pending
- 2021-10-29 PE PE2024000932A patent/PE20241211A1/es unknown
- 2021-10-29 MX MX2024005105A patent/MX2024005105A/es unknown
- 2021-10-29 CA CA3236111A patent/CA3236111A1/en active Pending
- 2021-10-29 WO PCT/US2021/057439 patent/WO2023075798A1/en not_active Ceased
- 2021-10-29 JP JP2024525160A patent/JP7846761B2/ja active Active
- 2021-10-29 KR KR1020247017366A patent/KR20240093915A/ko active Pending
-
2025
- 2025-09-18 JP JP2025155232A patent/JP2026004356A/ja active Pending